Standard Biotools INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Standard BioTools Inc.'s 2024 10-K filing reveals a year of strategic consolidation marked by the SomaLogic merger and Sengenics acquisition, aiming to enhance its life science tools portfolio.
NASDAQ
10-K/A: Standard BioTools Files Amended 10-K to Include Omitted Information and Updated Certifications
Standard BioTools has filed an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance, along with updated certifications from its CEO and CFO.
NASDAQ
Standard BioTools Inc. outlines its share structure, voting rights, and corporate governance policies in its latest 10-K filing, including details on common and preferred stock.